| Dr Adam Michael Donnelly, MD | |
|
1627 Chew St, Allentown, PA 18102-3648 | |
| (610) 969-4300 | |
| (610) 969-4332 |
| Full Name | Dr Adam Michael Donnelly |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 1627 Chew St, Allentown, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457794018 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | MD458717 (Pennsylvania) | Primary |
| Entity Name | Lehigh Valley Physician Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457309650 PECOS PAC ID: 3072425123 Enrollment ID: O20040227000335 |
News Archive
A Mayo Clinic discovery about a protein known as Dynamin-2 has thrown conventional wisdom for a loop. Finding the protein on the centrosome, a minute structure near a cell's nucleus, may lead to new strategies for stopping cancer growth.
In a new publication from Cardiovascular Innovations and Applications; Zhaowei Zhu, Jianjun Tang, Xiangping Chai and colleagues from Central South University, Changsha, Hunan, China analyse the similarities and differences of CT features between COVID-19 pneumonia and heart failure.
Targeted tumor radiation provides a feasible treatment option for children with difficult-to-treat liver cancer, according to a new study published today in the journal Pediatric Blood and Cancer.
Soligenix, Inc., a late-stage biopharmaceutical company, announced today that patient enrollment has been completed in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of orBec for the prevention of acute Graft-versus-Host disease after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens.
› Verified 9 days ago
| Entity Name | Valley Health Partners Community Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770118648 PECOS PAC ID: 4284065327 Enrollment ID: O20200505003199 |
News Archive
A Mayo Clinic discovery about a protein known as Dynamin-2 has thrown conventional wisdom for a loop. Finding the protein on the centrosome, a minute structure near a cell's nucleus, may lead to new strategies for stopping cancer growth.
In a new publication from Cardiovascular Innovations and Applications; Zhaowei Zhu, Jianjun Tang, Xiangping Chai and colleagues from Central South University, Changsha, Hunan, China analyse the similarities and differences of CT features between COVID-19 pneumonia and heart failure.
Targeted tumor radiation provides a feasible treatment option for children with difficult-to-treat liver cancer, according to a new study published today in the journal Pediatric Blood and Cancer.
Soligenix, Inc., a late-stage biopharmaceutical company, announced today that patient enrollment has been completed in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of orBec for the prevention of acute Graft-versus-Host disease after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Adam Michael Donnelly, MD Po Box 783311, Philadelphia, PA 19178-3311 Ph: (484) 884-4500 | Dr Adam Michael Donnelly, MD 1627 Chew St, Allentown, PA 18102-3648 Ph: (610) 969-4300 |
News Archive
A Mayo Clinic discovery about a protein known as Dynamin-2 has thrown conventional wisdom for a loop. Finding the protein on the centrosome, a minute structure near a cell's nucleus, may lead to new strategies for stopping cancer growth.
In a new publication from Cardiovascular Innovations and Applications; Zhaowei Zhu, Jianjun Tang, Xiangping Chai and colleagues from Central South University, Changsha, Hunan, China analyse the similarities and differences of CT features between COVID-19 pneumonia and heart failure.
Targeted tumor radiation provides a feasible treatment option for children with difficult-to-treat liver cancer, according to a new study published today in the journal Pediatric Blood and Cancer.
Soligenix, Inc., a late-stage biopharmaceutical company, announced today that patient enrollment has been completed in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of orBec for the prevention of acute Graft-versus-Host disease after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens.
› Verified 9 days ago
Dr. Ruchi Gupta, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 401 N 17th St, Suite 309, Allentown, PA 18104 Phone: 610-437-6687 | |
Dr. Douglas Mchale, DO Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1200 S Cedar Crest Blvd, Allentown, PA 18103 Phone: 610-402-7712 Fax: 224-484-1306 | |
Dr. Sajani Jitendra Sukhadia, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1611 Pond Rd Ste 400, Allentown, PA 18104 Phone: 610-402-8000 | |
Dr. Heather Noreen Becker, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1200 S Cedar Crest Blvd, Allentown, PA 18103 Phone: 610-402-9750 | |
Sara S Viessman, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1627 W Chew St, Suite 601, Allentown, PA 18102 Phone: 610-969-2555 | |
Paige Payne, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 450 Chew St Ste 203, Allentown, PA 18102 Phone: 484-503-3058 | |
Daniel Helmut Ublagger, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1200 S Cedar Crest Blvd Fl 6, Allentown, PA 18103 Phone: 610-402-7712 Fax: 484-224-1306 |